Literature DB >> 9855236

Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12 years.

G H Walenkamp1, L L Kleijn, M de Leeuw.   

Abstract

We treated 100 patients having osteomyelitis with debridement and gentamicin-PMMA beads and followed them for 5 (1-12) years. 66 of the infections were chronic, in 18 cases combined with arthritis and in 3 cases with pseudarthrosis. They underwent 117 "treatment periods", consisting of one or more operations (total 152), in most cases with an interval of 2 weeks. No systemic antibiotics were necessary besides the local antibiotic treatment in 52 of the treatment periods. Healing was achieved in 92 patients, in 78 after a single treatment period which included 1-5 operations, in 14 after two or three treatment periods. Healing was more difficult to achieve when the infection was chronic, especially with a duration of more than 6 years or when caused by elective surgery. Local antibiotic treatment with gentamicin PMMA beads has the advantage that the wound can be closed primarily and that a higher local antibiotic concentration in the tissues can be achieved, often making systemic antibiotic treatment unnecessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855236     DOI: 10.3109/17453679808997790

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  32 in total

1.  Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model.

Authors:  Christopher Faber; Hein P Stallmann; D M Lyaruu; Uwe Joosten; Christof von Eiff; Arie van Nieuw Amerongen; Paul I J M Wuisman
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  [Therapeutic strategies for joint infections].

Authors:  U-J Gerlach
Journal:  Chirurg       Date:  2018-02       Impact factor: 0.955

3.  Chronic osteomyelitis.

Authors:  Ilker Uçkay; Kheeldass Jugun; Axel Gamulin; Joe Wagener; Pierre Hoffmeyer; Daniel Lew
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

4.  The effectiveness of the controlled release of gentamicin from polyelectrolyte multilayers in the treatment of Staphylococcus aureus infection in a rabbit bone model.

Authors:  Joshua S Moskowitz; Michael R Blaisse; Raymond E Samuel; Hu-Ping Hsu; Mitchel B Harris; Scott D Martin; Jean C Lee; Myron Spector; Paula T Hammond
Journal:  Biomaterials       Date:  2010-05-21       Impact factor: 12.479

5.  Salvage of Infected Prosthetic Breast Reconstructions.

Authors:  Amy S Xue; Katarzyna E Kania; Rodger H Brown; Jamal M Bullocks; Larry H Hollier; Shayan A Izaddoost
Journal:  Semin Plast Surg       Date:  2016-05       Impact factor: 2.314

Review 6.  Biomaterials approaches to treating implant-associated osteomyelitis.

Authors:  Jason A Inzana; Edward M Schwarz; Stephen L Kates; Hani A Awad
Journal:  Biomaterials       Date:  2015-12-18       Impact factor: 12.479

7.  Successful treatment of chronic osteomyelitis in children with debridement, antibiotic-laden cement spacer and bone graft substitute.

Authors:  Federico Canavese; Marco Corradin; Ahmad Khan; Mounira Mansour; Marie Rousset; Antoine Samba
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-09-19

8.  Bio-absorbable antibiotic impregnated beads for the treatment of prosthetic vascular graft infections.

Authors:  Elizabeth A Genovese; Efthymios D Avgerinos; Donald T Baril; Michel S Makaroun; Rabih A Chaer
Journal:  Vascular       Date:  2016-02-18       Impact factor: 1.285

9.  Treatment of osteomyelitis in rats by injection of degradable polymer releasing gentamicin.

Authors:  Yaron S Brin; Jacob Golenser; Boaz Mizrahi; Guy Maoz; Abraham J Domb; Shyamal Peddada; Shmuel Tuvia; Abraham Nyska; Meir Nyska
Journal:  J Control Release       Date:  2008-07-20       Impact factor: 9.776

10.  [Principles of surgical therapy concepts for postoperative and chronic osteomyelitis].

Authors:  F Kutscha-Lissberg; U Hebler; T Kälicke; S Arens
Journal:  Orthopade       Date:  2004-04       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.